For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenue | - | - | - | 2,446 |
| Research and development | - | - | - | 3,551,302 |
| General and administrative | - | - | - | 2,289,015.25 |
| License fee expense | - | - | - | 25,000 |
| Loss from operations | -3,672,148 | -3,827,800 | - | - |
| Total operating expenses | - | - | - | 5,865,317.25 |
| Sale of royalty and milestone rights, net | 0 | 0 | - | - |
| Loss from operations | - | - | - | -5,862,871.25 |
| Interest expense | 213,171 | 268,533 | - | - |
| Sale of royalty and milestone rights, net of transaction costs (note 13) | - | - | - | 5,094,844 |
| Interest income | 319,147 | 69,848 | - | - |
| Other (expense) income | - | - | - | -245,372.5 |
| Other income (expense), net | 3,406 | 10,002 | - | - |
| Net income (loss) | -3,562,766 | -4,016,483 | -4,378,307 | -1,013,399.75 |
| Net loss to common stockholders | - | - | - | -1,013,399.75 |
| Foreign currency translation adjustments | 6,860 | - | 13,090 | -16,978.25 |
| Comprehensive income (loss) | -3,555,906 | - | -4,365,217 | -1,030,378 |
| Basic (in shares) | 12,755,112 | 8,871,155 | 8,759,053 | 2,124,364.75 |
| Diluted (in shares) | 12,755,112 | 8,871,155 | 8,759,053 | 2,124,364.75 |
| Income (loss) per common share - basic (in usd per share) | -0.28 | -0.45 | -0.5 | -0.12 |
| Income (loss) per common share - diluted (in usd per share) | -0.28 | -0.45 | -0.5 | -0.12 |
Dare Bioscience, Inc. (DARE)
Dare Bioscience, Inc. (DARE)